TransMedics Group (MIL:1TMDX) Total Noninterest Expense

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1TMDX TransMedics Group Inc MIL:1TMDX
54 GF Score
Price €78.22
GF Value €136.93
Valuation Possible Value Trap
! 9 Warning Signs
View Full Analysis

What is TransMedics Group Total Noninterest Expense?

Total Noninterest Expense only applies to banks.

MIL:1TMDX
54GF Score
TransMedics Group Inc MIL:1TMDX
Total Noninterest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is TransMedics Group (MIL:1TMDX) Overvalued in 2026?

Based on GuruFocus' analysis, TransMedics Group stock appears to be undervalued. The current stock price of €78.22 is trading 42.9% below its estimated GF Value™ of €136.93. GuruFocus considers TransMedics Group to be Possible Value Trap.

Key valuation signals for MIL:1TMDX:

  • Total Noninterest Expense:
  • GF Value™: €136.93 vs. price of €78.22 (42.9% below fair value)
  • GF Score™: 54/100 with 9 warning signs

No single metric tells the full story. See the MIL:1TMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TransMedics Group Business Description

Address 200 Minuteman Road, Andover, MA, USA, 01810
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
54GF Score

Get the complete analysis for MIL:1TMDX

Total Noninterest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€78.22
Price
€136.93
GF Value